^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SLC6A6 (Solute Carrier Family 6 Member 6)

    i
    Other names: SLC6A6, Solute Carrier Family 6 Member 6, TAUT, Solute Carrier Family 6 (Neurotransmitter Transporter, Taurine), Member 6, Sodium- And Chloride-Dependent Taurine Transporter, Solute Carrier Family 6 (Neurotransmitter Transporter), Member 6, Taurine Transporter, HTRDC
    Associations

    News

    Trials
    17d
    SLC6A6 imports taurine into mitochondria to sustain mitochondrial translation and tumour growth. (PubMed, Nat Metab)
    Furthermore, we identify NFAT5 as a key regulator of mitochondrial function through SLC6A6 and demonstrate that targeting the NFAT5-SLC6A6 axis markedly impairs mitochondrial translation and tumour growth. Together, these findings suggest that SLC6A6 is a mitochondrial taurine transporter and an exploitable metabolic dependency in cancer.
    Journal
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    27d
    The Taurine-Slc6a6 Axis Promotes Breast Cancer Progression by Alleviating Oxidative Stress and Accelerating Cell Cycle Progression. (PubMed, Cells)
    Second, beyond its metabolic role, Slc6a6 directly interacts with the cell cycle regulator Rprd1b to promote the G1/S phase transition, leading to uncontrolled proliferation. Clinically, bioinformatics analyses correlate high SLC6A6 expression with poor prognosis in breast cancer patients, underscoring its potential as a therapeutic target.
    Journal
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    28d
    Taurine Facilitates the Formation of Hepatocellular Carcinoma via the Bile Acid Pathway. (PubMed, Metabolites)
    Our findings demonstrate that taurine plays a vital role in the tumor-promoting activities of HCC.
    Journal
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    2ms
    Taurine transporter SLC6A6 expression promotes mesenchymal stromal cell function. (PubMed, Cell Death Dis)
    Mechanistically, TauT loss results in downregulation of inositol metabolism, increased oxidative stress, and reduced Wnt/β-catenin signaling, which induce MSC senescence. Collectively, our data identifies taurine as a key regulator of MSC maintenance and osteogenic fate determination.
    Journal
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    4ms
    High glucose promotes cisplatin chemoresistance in MDA-MB-231 breast cancer derived cells through changes in gene expression and multiple signaling pathways. (PubMed, Biomed Rep)
    Notably, these include the Wnt/β-catenin axis. Candidate biomarkers with potential prognostic and therapeutic relevance in diabetic breast cancer (BC) were also identified.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • AREG (Amphiregulin) • CD70 (CD70 Molecule) • IGF1 (Insulin-like growth factor 1) • CASP3 (Caspase 3) • APP (Amyloid Beta Precursor Protein) • CDH2 (Cadherin 2) • EHD1 (EH Domain Containing 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2) • FZD3 (Frizzled Class Receptor 3) • RAD17 (RAD17 Checkpoint Clamp Loader Component) • SLC6A6 (Solute Carrier Family 6 Member 6)
    |
    cisplatin
    7ms
    Association between taurine transporter SLC6A6 and breast cancer development and prognosis: a Mendelian randomization analysis. (PubMed, Discov Oncol)
    Taurine metabolic reprogramming can serve as a potential marker for early breast cancer diagnosis. SLC6A6 participates in breast cancer progression by regulating taurine levels and influencing immune infiltration, representing an independent predictor of breast cancer prognosis and a potential therapeutic target.
    Journal
    |
    CD14 (CD14 Molecule) • SLC6A6 (Solute Carrier Family 6 Member 6)
    8ms
    Primary pigmented papillary epithelial tumor of the sella: case report and literature review. (PubMed, Brain Tumor Pathol)
    PPPET has unique morphologic, immunohistochemical, and molecular genetic characteristics. Our findings suggest that PPPET may be an independent neurooncological entity.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • MLANA (Melan-A) • SYP (Synaptophysin) • DDX10 (DEAD-Box Helicase 10) • GFAP (Glial Fibrillary Acidic Protein) • SLC6A6 (Solute Carrier Family 6 Member 6)
    8ms
    A Gene Signature Developed Based on Reactive Oxygen Species to Predict the Metabolism, Immunity, Mutational Status, and Prognostic Survival for Glioblastoma. (PubMed, Curr Med Chem)
    The ROS-associated risk model could accurately predict tumor immunity and progression for GBM patients, acting as an effective predictor of GBM prognosis. The present discovery provided a novel understanding of the diagnosis and treatment of GBM patients.
    Journal • Gene Signature
    |
    OSMR (Oncostatin M Receptor) • SLC6A6 (Solute Carrier Family 6 Member 6)
    1year
    Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning. (PubMed, Sci Rep)
    Similarly, RT-QPCR demonstrated that SLC6A6 was significantly downregulated in Tra-treated cardiomyocytes in vitro and in vivo. Our study suggests that the differential expression of SLC6A6 in vitro and in vivo models is associated with TIC, which may be a candidate diagnostic gene for the early occurrence and development of TIC and a potential therapeutic target.
    Journal • Machine learning
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    |
    Herceptin (trastuzumab)
    over1year
    Unveiling the role of taurine and SLC6A6 in tumor immune evasion: Implications for gastric cancer therapy. (PubMed, Int J Biochem Cell Biol)
    Our work further explored the potential, advantages, and challenges of using taurine and SLC6A6 as biomarkers and therapeutic targets in gastric cancer. We aim to underscore their importance in both basic research and clinical applications, providing valuable insights and guidance for future investigations.
    Journal
    |
    CD8 (cluster of differentiation 8) • SLC6A6 (Solute Carrier Family 6 Member 6)
    over1year
    Structural Studies of the Taurine Transporter: A Potential Biological Target from the GABA Transporter Subfamily in Cancer Therapy. (PubMed, Int J Mol Sci)
    The significance of selected residues was confirmed through structural studies of mutants. These results will aid in the development of novel taurine transporter inhibitors, which can be explored as anticancer agents.
    Journal
    |
    SLC6A6 (Solute Carrier Family 6 Member 6)
    almost2years
    Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. (PubMed, Cell)
    In gastric cancer, we identify a chemotherapy-induced SP1-SLC6A6 regulatory axis. Our findings suggest that tumoral-SLC6A6-mediated taurine deficiency promotes immune evasion and that taurine supplementation reinvigorates exhausted CD8+ T cells and increases the efficacy of cancer therapies.
    Journal
    |
    CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • ATF4 (Activating Transcription Factor 4) • SLC6A6 (Solute Carrier Family 6 Member 6)